bpc 157 safety regulatory status fda bpc-157 The FDA just announced that they're taking steps to EVEXIAS Life Sciences filing lawsuit
Description
Carrasco, C
For providers, having a potent oral option improves long-term adherence for patients who are averse to subcutaneous injections
The compounds safety and pharmacological profile have been comprehensively assessed in rodent models.In preclinical trials, including those involving ovariectomized (OVX) rat models, both low- and high-dose AOD-9604 regimens showed no significant toxicity
Today, it refers specifically to B12 deficiency anemia resulting from antibodies that inhibit B12 absorption
